Rinvoq Side Effects in Crohn's: What Patients Actually Report

Rinvoq's FDA label carries a boxed warning for serious infections, mortality, malignancy, major adverse cardiovascular events (MACE) and thrombosis (1). The reactions Crohn's patients report most often are far more ordinary: upper respiratory tract infection in 13 percent, anemia in 7 percent and acne in 6 percent (1). Checked 2026-10-01. Both are true at once, and understanding rinvoq side effects means holding them together rather than picking one.

Many of us have read a boxed warning and decided, right there, not to take the drug. This article explains each heading in ordinary words, then separates that warning from what patients actually experience. For how Rinvoq works, plus efficacy, dosing and cost, see our full Rinvoq patient guide.

Key Takeaways

• The boxed warning covers serious infections, mortality, malignancy, major adverse cardiovascular events and thrombosis (1).
• That mortality and MACE signal came from a rheumatoid arthritis trial of a different JAK inhibitor, not the Crohn's programme (1).
• The most common rinvoq side effects in the Crohn's trials: upper respiratory tract infection 13 percent, anemia 7 percent, acne 6 percent (1).
• Treatment pauses if neutrophils fall under 1000 cells/mm3, lymphocytes under 500 cells/mm3, or hemoglobin under 8 g/dL (1).
• In a UK cohort of 312 heavily treated patients, 18 percent had a serious adverse event, yet 84.1 percent stayed on at 24 weeks (2).
• Herpes zoster, neutropenia and hepatic disorders rose dose-dependently in maintenance, so 30 mg is watched more closely than 15 mg (4).

The FDA Boxed Warning, Explained in Plain Language

Rinvoq carries a boxed warning, the strongest the FDA applies to a prescription medicine. Its heading reads: serious infections, mortality, malignancy, major adverse cardiovascular events (MACE) and thrombosis (1). That is a warning about five categories of serious harm. It stands, and it is also not a prediction about any one patient.

What the five headings actually mean

In ordinary words, the label describes these risks (1):

• Serious infections. Bacterial, fungal and viral infections, including tuberculosis, that can require hospital care.
• Mortality. A higher rate of death, including sudden cardiovascular death, seen with another JAK inhibitor compared with TNF blockers in rheumatoid arthritis.
• Malignancy. Cancers, including lymphoma and lung cancer.
• MACE. Heart attack and stroke.
• Thrombosis. Blood clots in the legs or lungs.

Where the evidence behind the warning came from

This is the part most side effect pages leave out. The mortality and MACE signal came not from the Crohn's programme but from a rheumatoid arthritis trial of a different JAK inhibitor, measured against TNF blockers (1).

Saying so is not minimising the warning, which the FDA applied to this class deliberately. But a patient weighing a decision is entitled to know which population and which drug produced those numbers.

Who carries more of this risk

The label does not spread the risk evenly. It flags higher risk in people aged 50 and over with at least one cardiovascular risk factor, and in current or former smokers, who carry more of the malignancy and MACE risk (1). Rinvoq is not recommended in severe hepatic impairment (Child-Pugh C) (1).

One risk is specific to the gut: pooled upadacitinib analyses describe rare but serious intestinal perforations, especially at higher doses (4).

The Side Effects Most Crohn's Patients Actually Get

In the phase 3 Crohn's programme, the adverse reactions reported in at least 2 percent of patients were upper respiratory tract infection 13 percent, anemia 7 percent, acne 6 percent, pyrexia or fever 4 percent, increased blood creatine phosphokinase 3 percent, influenza 3 percent and herpes simplex 3 percent (1). None appears in the boxed warning.

What the Crohn's label table shows

Those figures come from the Crohn's trials specifically, where 45 mg was studied for 12 weeks of induction and 15 mg or 30 mg for maintenance (1). That matters: upadacitinib is approved across several conditions at different doses, so percentages quoted online are often from rheumatology.

Acne: the one almost nobody warns you about

Acne reached 6 percent in the Crohn's label (1). It is cosmetic rather than dangerous, and it blindsides adults who have not had a breakout since their teens.

Real-world cohorts find it too: 4.5 percent in the 312-patient UK cohort (2), and rash in 6.4 percent of a 108-patient anti-TNF refractory cohort (3). In our community it is a common reason people search for side effect information only after starting. The honest limit: the evidence here does not quantify how often it resolves.

Anemia, fever and muscle enzyme changes

Anemia at 7 percent and fever at 4 percent sit near the top of the list (1), and both overlap with active Crohn's itself, which is why these tables cannot fully separate drug from disease.

Raised creatine phosphokinase, at 3 percent, alarms people who look it up and find a muscle enzyme. It is a blood test change rather than a muscle problem, and a systematic review states its significance is still unclear (4).

What Real-World Crohn's Cohorts Report

Two published Crohn's cohorts describe what happened outside a trial protocol, and both look worse on paper than the trials. Across 312 UK patients, 28 percent had any adverse event and 18 percent a serious one (2). In 108 anti-TNF refractory patients, 20.3 percent had one (3). For this class outside trials, see our JAK inhibitor real-world results article.

A 312-patient UK cohort

A multicentre retrospective cohort followed 312 patients across 19 hospitals, a difficult-to-treat group in which 64 percent had already failed three or more biologics (2). It reported:

• Any adverse event 28 percent, serious adverse events 18 percent
• Hospitalization 16.6 percent, infections 7.7 percent
• Acne 4.5 percent, herpes zoster 1.3 percent, venous thromboembolism 1.0 percent
• Persistence on the drug 90.3 percent at 12 weeks and 84.1 percent at 24 weeks (2)

A 108-patient anti-TNF refractory cohort

A separate cohort of 108 anti-TNF refractory patients was followed for a median of six months. Twenty-two patients (20.3 percent) had an adverse event: rash 6.4 percent, fever 4.6 percent, zoster infection 1.8 percent, elevated liver enzymes 1.8 percent, hypercholesterolemia 1.8 percent, leukopenia 0.9 percent. Three stopped because of an adverse event, and no serious cardiovascular events or malignancies were reported (3).

Why real-world numbers run higher than trial numbers

Three plain reasons. They enroll sicker, more heavily treated patients than a trial would accept. They count hospitalizations for Crohn's itself alongside drug side effects, so a flare lands in the same column as a drug reaction. And follow-up is short.

Those limits cut both ways: at 312 and 108 patients over months, neither cohort is remotely large or long enough to prove or disprove the boxed warning risks.

Blood Tests and Monitoring: What Gets Checked and When

The label directs clinicians to evaluate absolute neutrophil count, absolute lymphocyte count, hemoglobin and liver enzymes at baseline and thereafter according to routine patient management, and to assess lipids roughly 12 weeks after starting and then per clinical guidelines (1). This is the trade-off for an oral drug: no infusion chair, but real lab appointments.

Before your first dose

The Crohn's & Colitis Foundation's fact sheet on this drug class says a care team will typically order blood counts, screening for chronic infections including tuberculosis and hepatitis B, liver and kidney function, and cholesterol before starting (5). One caveat: that fact sheet predates the Crohn's approval and names only the ulcerative colitis indication, so read it as orientation to the drug class.

What the label says to watch

"Baseline and thereafter according to routine patient management" is deliberately open wording, which is why intervals differ between clinics and countries. If nobody has given you the plan, ask at the next appointment.

The numbers that pause treatment

The label instructs clinicians to interrupt treatment if (1):

• Absolute neutrophil count falls under 1000 cells/mm3
• Absolute lymphocyte count falls under 500 cells/mm3
• Hemoglobin falls under 8 g/dL

A systematic review covering seven studies and 1,481 patients found herpes zoster, neutropenia and hepatic disorders increased dose-dependently during maintenance (4), which is why 30 mg is watched more closely than 15 mg.

Shingles, Vaccines and Pregnancy

The label recommends bringing all immunizations up to date before starting Rinvoq, including prophylactic varicella zoster or herpes zoster vaccination, and avoiding live vaccines during therapy or immediately before starting it (1). Timing matters, because the window for some vaccines closes once treatment begins.

Get the shingles vaccine before you start

Herpes zoster appears in the real-world cohorts at 1.3 percent (2) and 1.8 percent (3), and rises with dose during maintenance (4). The Foundation notes the two-dose inactivated shingles vaccine series is not a live vaccine, which is why it is the one people on these medications can have (5). Our guide to vaccines for Crohn's patients covers what to bring up to date first. If shingles occurs, the label says to consider temporarily interrupting Rinvoq until it resolves (1).

Live vaccines are off the table

Live vaccines are to be avoided during therapy and immediately before starting (1). Which products count as live varies by country, so ask the prescribing team rather than settling it from a US label.

Pregnancy and contraception

The label advises females of reproductive potential about potential fetal risk, and recommends effective contraception during treatment and for 4 weeks after finishing (1). Animal studies showed fetal malformations and lower fetal body weights (1).

The Foundation adds that data are insufficient to establish a risk of major birth defects or miscarriage in humans, and recommends discussing pregnancy plans before starting (5).

Who Should Think Twice, and When to Call Your Doctor

The label singles out three groups for extra caution: people aged 50 and over with at least one cardiovascular risk factor, current or past smokers, who carry more of the malignancy and MACE risk, and people with severe hepatic impairment, where Rinvoq is not recommended (1). Being in one of those groups is not an automatic no.

Groups the label singles out

If one of those fits, the useful conversation is comparative: this risk profile against the alternatives open to you, and against leaving Crohn's inflammation untreated. For readers weighing Rinvoq against biologics, our IBD medications comparison guide sets the classes side by side. One limit: no head-to-head safety trial of Rinvoq against biologics in Crohn's appears in the evidence here, so any comparison is assembled from separate datasets.

Symptoms that need a same-day call

These are worth a call rather than a wait:

• Fever, chills, night sweats, sore throat or any other sign of infection (5)
• A new painful blistering rash in a band on one side of the body, which can be shingles (1)(5)
• Leg swelling or pain, chest pain or sudden breathlessness, which can signal a clot (1)
• Sudden severe abdominal pain, given the reports of intestinal perforation (4)

One thing not to do: stop Rinvoq abruptly on your own. Reducing the dose from 30 mg to 15 mg is a lever a gastroenterologist has, partly because several dose-dependent problems ease at 15 mg (4). Most people in the cohorts stayed on the drug, with UK persistence of 84.1 percent at 24 weeks (2). A side effect is not automatically the end of treatment.

Frequently Asked Questions

Does Rinvoq cause acne, and does it go away?

Acne was reported in 6 percent of patients in the Crohn's label (1), 4.5 percent in a 312-patient UK cohort (2), and rash in 6.4 percent of a 108-patient anti-TNF refractory cohort (3). The evidence here does not quantify how often it clears.

Does Rinvoq cause cancer?

Malignancy, including lymphoma and lung cancer, is one of the five boxed warning headings, and the label flags higher risk in current or former smokers (1). The real-world cohorts reported no malignancies (3), but neither is large or long enough to settle it, and a systematic review states long-term data on malignancy risk remain incomplete (4).

Do I need blood tests forever?

The label asks for neutrophil count, lymphocyte count, hemoglobin and liver enzymes at baseline and thereafter according to routine patient management, plus a lipid assessment about 12 weeks in (1). That wording leaves the interval to your care team, so schedules differ between clinics.

Can I get the shingles vaccine on Rinvoq?

The two-dose inactivated shingles vaccine series is not a live vaccine, so it can be considered for people on these medications (5), and the label recommends prophylactic varicella zoster or herpes zoster vaccination before starting (1). Live vaccines are not an option during therapy.

Is 15 mg safer than 30 mg?

A systematic review of seven studies covering 1,481 patients found dose-dependent increases in herpes zoster, neutropenia and hepatic disorders during maintenance, plus rare but serious intestinal perforations at higher doses (4). That is why 30 mg is monitored more closely, though it does not make 30 mg wrong: the higher dose exists for disease that needs it.

References

1. US Food and Drug Administration via DailyMed. RINVOQ (upadacitinib) extended-release tablets and RINVOQ LQ oral solution, full prescribing information. 2025. Checked 2026-10-01. Read the prescribing information
2. Multicentre UK study group. Effectiveness and safety of upadacitinib in a real-world cohort of patients with Crohn's disease in the UK: a multicentre retrospective cohort study. 2025. Checked 2026-10-01. Read the study
3. Study authors. A Real-World Study of Upadacitinib in Anti-TNF Refractory Crohn's Disease: Effectiveness, Persistence, and Safety. 2026. Checked 2026-10-01. Read the study
4. Review authors. Safety and Efficacy of Upadacitinib in Crohn's Disease: An Updated Systematic Review. 2024. Checked 2026-10-01. View on PubMed Central
5. Crohn's & Colitis Foundation. Targeted Synthetic Small Molecules (Fact Sheet, News from the IBD Help Center). 2022. Checked 2026-10-01. Read the fact sheet